TP53BP1 and breast carcinoma: While shRNA-mediated 53BP1 depletion led to overt resistance to olaparib in BRCA1-mutated breast cancer SUM149 cells, no effect was seen in RB1-defective osteosacrcoma OHSN or SAOS2 cells.